Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07486726 | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07483749 | HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors | not yet recruiting | — | 400 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 |
| Mar 19, 2026 |
| clinicaltrials |
| NCT07476027 | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) | not yet recruiting | Phase 3 | 750 | Charite University, Berlin, GermanyOTHER | 20 | Mar 17, 2026 | clinicaltrials |
| NCT07477769 | Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)(NIPALYMPHO) | not yet recruiting | — | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07372885 | GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia(GRACE) | not yet recruiting | Phase 1 / Phase 2 | 50 | University of ManchesterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07463768 | Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.(MIVONU) | not yet recruiting | Phase 2 | 60 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07462299 | NUDT15/TPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy | not yet recruiting | N/A | 110 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07060001 | Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker | not yet recruiting | Phase 2 | 112 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07449286 | IFN-α in Relapse Prevention. | not yet recruiting | Phase 2 | 100 | Peking University People's HospitalOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05565105 | CD34+ Transplants for Leukemia and Lymphoma | not yet recruiting | Phase 2 | 100 | Guenther KoehneOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07441980 | A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07443592 | Treatment for Ph-negative ALL for Adults up to 65 Years(LAL-2025) | not yet recruiting | N/A | 330 | PETHEMA FoundationOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07432100 | Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 20 | Mingfeng ZhaoOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07425808 | FLT3-ITD Targeted Therapy in Fit AML Patients(FIT-AML) | not yet recruiting | Phase 2 / Phase 3 | 230 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 23, 2026 | clinicaltrials |
| NCT07423104 | A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 24 | University of RochesterOTHER | 0 | Feb 20, 2026 | clinicaltrials |
| NCT07413263 | Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients | not yet recruiting | — | 75 | Assiut UniversityOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07392814 | Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia(TOCIVENA) | not yet recruiting | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407660 | Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax | not yet recruiting | Phase 3 | 250 | Peking University People's HospitalOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT06991920 | Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage | not yet recruiting | N/A | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 11, 2026 | clinicaltrials |
| NCT07386392 | Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia(HYPNO-RV LAM) | not yet recruiting | N/A | 99 | University Hospital, ToulouseOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07383233 | CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma | not yet recruiting | Phase 1 | 18 | Qi dengOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT07371533 | Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319)(A-319) | not yet recruiting | N/A | 18 | Shanxi Bethune HospitalOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07370064 | Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia(AML CAR-T) | not yet recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(IASO104) | not yet recruiting | Early Phase 1 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07342244 | Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | N/A | 18 | Donghua ZhangOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07343687 | Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy . | not yet recruiting | — | 80 | Assiut UniversityOTHER | 0 | Jan 15, 2026 | clinicaltrials |
| NCT07320534 | Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase | not yet recruiting | Phase 4 | 124 | Gadjah Mada UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07319793 | Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT | not yet recruiting | N/A | 200 | Peking University People's HospitalOTHER | 0 | Jan 6, 2026 | clinicaltrials |
| NCT07296445 | A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)(LATITUDE) | not yet recruiting | Phase 3 | 120 | SDK Therapeutics, Inc.INDUSTRY | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07166549 | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)(BaseCAR-01) | not yet recruiting | Phase 1 | 12 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07301138 | BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients | not yet recruiting | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07297914 | Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL(FORUM2) | not yet recruiting | Phase 2 / Phase 3 | 1,000 | Bambino Gesù Hospital and Research InstituteOTHER | 9 | Dec 22, 2025 | clinicaltrials |
| NCT07286539 | Precision Physical Exercise for Personalized Onco-Hematology.(PEPOH) | not yet recruiting | N/A | 150 | University of SalamancaOTHER | 0 | Dec 16, 2025 | clinicaltrials |
| NCT07277504 | Autologous Bedside CD19 CAR T-cell Therapy for B-ALL | not yet recruiting | Early Phase 1 | 50 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06906380 | A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies | not yet recruiting | — | 49 | ARCE Therapeutics, Inc.INDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07269067 | Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)(DUALFLOW) | not yet recruiting | — | 60 | University Hospital, BordeauxOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07264010 | Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | not yet recruiting | Phase 2 / Phase 3 | 87 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Dec 4, 2025 | clinicaltrials |
| NCT07259161 | Modified Conditioning Regimen for CML-BP | not yet recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07256353 | Allogeneic UCB-derived CAR-T for B-ALL | not yet recruiting | Early Phase 1 | 50 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07233018 | A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 24 | MEI HENGOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07213882 | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)(CITY) | not yet recruiting | Early Phase 1 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 9, 2025 | clinicaltrials |
| NCT07214064 | Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation | not yet recruiting | Phase 2 | 27 | University Hospital TuebingenOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT07200882 | What is the Impact of TKI on Thyroid Function in CML Patients? | not yet recruiting | — | 76 | Assiut UniversityOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT07201727 | CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT06979076 | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | not yet recruiting | Phase 1 / Phase 2 | 12 | MingSight Pharmaceuticals, IncINDUSTRY | 0 | Sep 29, 2025 | clinicaltrials |
| NCT06281847 | An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia(RESOLVE AML001) | not yet recruiting | Phase 1 / Phase 2 | 143 | Advesya SASINDUSTRY | 4 | Sep 18, 2025 | clinicaltrials |
| NCT07107204 | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 116 | Biotroy TherapeuticsINDUSTRY | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07175415 | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART E) | not yet recruiting | Phase 1 / Phase 2 | 42 | Princess Maxima Center for Pediatric OncologyOTHER | 0 | Sep 16, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 20, 2026source: clinicaltrials